Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia

NCT05413135 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT05413135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2022
Completion date
September 22, 2025
Enrollment
418 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias